Ado-trastuzumab emtansine led to improved overall survival and invasive disease–free survival over trastuzumab in patients ...
T-DM1 reduced risk of invasive disease events and death compared with trastuzumab in HER2-positive early breast cancer with ...
In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...
T-DM1 was tolerable in HER2-positive biliary tract adenocarcinoma but did not significantly improve progression-free survival ...
Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has ...
Trastuzumab emtansine as second-line therapy in HER2 positive advanced biliary tract cancers: Single arm prospective phase II clinical trial (TAB-3 trial). This is an ASCO Meeting Abstract from the ...
These drugs, discovered decades ago, continue to save lives today, but more recent research has led to the development of ...
and Roche's Kadcyla (trastuzumab emtansine) – both HER2-targeting ADCs – but may raise questions about its confidence in Tukysa. That said, RemeGen and Seagen are targeting gastric ...
Interventional procedures guidance Transcatheter tricuspid valve replacement for the reduction of tricuspid regurgitation Interventional procedures guidance Trastuzumab deruxtecan for adjuvant ...